LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

LLY

847.13

-6.39%↓

UNH

564.14

-1.53%↓

NVO

129.84

-4.18%↓

JNJ

155.3

-0.67%↓

MRK

124.28

-1.21%↓

Search

Amgen Inc

Avatud

Sektor Tervishoid

335.9 0.03

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

333.12

Max

338.66

Põhinäitajad

By Trading Economics

Sissetulek

-880M

-113M

Müük

-746M

7.5B

P/E

Sektori keskmine

22.76

79.786

Aktsiakasum

3.96

Kasumimarginaal

-1.517

Töötajad

26,700

EBITDA

-1.5B

2.2B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-3.81 downside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2024

Järgmine dividendimakse kuupäev

6. sept 2024

Järgmine aktsia dividendi kuupäev (ex-date)

15. aug 2024

Turustatistika

By TradingEconomics

Turukapital

12B

178B

Eelmine avamishind

335.87

Eelmine sulgemishind

335.9

Uudiste sentiment

By Acuity

25%

75%

41 / 369 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Amgen Inc Graafik

Seotud uudised

2. mai 2024, 20:42 UTC

Tulu

Amgen Posts Higher 1Q Revenue, Swings to Loss

6. veebr 2024, 21:48 UTC

Tulu

Amgen 4Q Revenue Surges as Acquisition Boosts Results

19. juuni 2024, 05:30 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

3. mai 2024, 14:43 UTC

Kuumad aktsiad

Stocks to Watch Friday: Apple, Amgen, Exxon, Coinbase -- WSJ

3. mai 2024, 11:43 UTC

Market Talk
Tulu

Amgen's Weight-Loss Drug Prospects Win New Bull -- Market Talk

3. mai 2024, 08:45 UTC

Tulu
Kuumad aktsiad

Stocks to Watch Friday: Apple, Amgen, Block -- WSJ

3. mai 2024, 08:28 UTC

Tulu

These Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Block, Coinbase, Cloudflare, Fortinet, and More -- Barrons.com

2. mai 2024, 20:04 UTC

Tulu

Amgen: FY Share Repurchases Not to Exceed $500 M >AMGN

2. mai 2024, 20:04 UTC

Tulu

Amgen Sees FY Capital Expenditure About $1.1B >AMGN

2. mai 2024, 20:03 UTC

Tulu

Amgen 1Q Adj EPS $3.96 >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen 1Q Worldwide Enbrel Sales $567M >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen 1Q Worldwide Prolia Sales $999M >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen 1Q Worldwide XGEVA Sales $561M >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen 1Q Rev $7.45B >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen 1Q Worldwide Neulasta Sales $118M >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen Sees FY EPS $7.15-EPS $8.40 >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen Sees FY Adj EPS $19.00-Adj EPS $20.20 >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen 1Q Loss/Shr 21c >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen 1Q Loss $113M >AMGN

2. mai 2024, 20:01 UTC

Tulu

Amgen Sees FY Rev $32.5B-$33.8B >AMGN

11. apr 2024, 14:46 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

6. veebr 2024, 21:44 UTC

Tulu

Amgen Rides Nine Record-Making Products To A Fourth-Quarter Sales Beat -- IBD

6. veebr 2024, 21:01 UTC

Tulu

Amgen Sees FY Rev $32.4B-$33.8B >AMGN

6. veebr 2024, 21:01 UTC

Tulu

Amgen 4Q EPS $1.42 >AMGN

6. veebr 2024, 21:01 UTC

Tulu

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

6. veebr 2024, 21:01 UTC

Tulu

Amgen 4Q Net $767M >AMGN

6. veebr 2024, 21:01 UTC

Tulu

Amgen 4Q Worldwide Prolia Sales $1.11B >AMGN

6. veebr 2024, 21:01 UTC

Tulu

Amgen 4Q Worldwide Neulasta Sales $239M >AMGN

6. veebr 2024, 21:01 UTC

Tulu

Amgen 4Q Worldwide XGEVA Sales $527M >AMGN

6. veebr 2024, 21:01 UTC

Tulu

Amgen 4Q Rev $8.2B >AMGN

Võrdlus sarnastega

Hinnamuutus

Amgen Inc Prognoos

Hinnasiht

By TipRanks

-3.81% langus

12 kuu keskmine prognoos

Keskmine 322.88 USD  -3.81%

Kõrge 380 USD

Madal 215 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Amgen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

21 ratings

12

Osta

8

Hoia

1

Müü

Tehniline skoor

By Trading Central

327.9899 / 335.91Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

41 / 369 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.